- Home
- AMAL vs PCRX Comparison
AMAL vs PCRX Comparison
Compare AMAL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | PCRX |
|---|---|---|
| Founded | 1923 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | AMAL | PCRX |
|---|---|---|
| Price | $41.94 | $23.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $36.00 | $30.25 |
| AVG Volume (30 Days) | 114.6K | ★ 470.0K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | ★ 0.84 | 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $21.18 | $6.78 |
| Revenue Next Year | $6.55 | $8.54 |
| P/E Ratio | ★ $49.96 | $336.29 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $25.13 | $18.80 |
| 52 Week High | $44.01 | $27.64 |
Technical Indicators
Market Signals| Indicator | AMAL | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 44.03 |
| Support Level | $36.50 | $20.27 |
| Resistance Level | $43.33 | $24.20 |
| Average True Range (ATR) | 1.31 | 1.26 |
| MACD | -0.05 | -0.24 |
| Stochastic Oscillator | 77.16 | 6.11 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.